Donanemab (Kisunla) records are Alzheimer's or related amyloid studies unless the registry says otherwise. Imaging and APOE-related exclusions can appear. Read the NCT eligibility block. Search the same name on ClinicalTrials.gov.
Also tagged in this snapshot for: Alzheimer Disease · Mild Cognitive Impairment · Dementia · Subjective Cognitive Decline (SCD) · Preclinical Alzheimer's Disease · Prodromal Alzheimer's Disease · Autosomal Dominant Alzheimers Disease · Early Onset Alzheimer Disease · Alzheimers Disease · Cognitive Dysfunction · Lewy Body Disease · Synucleinopathies
RecruitingNot a traditional drug phaseHuntsville, Alabama
Not a traditional drug phase: testing Donanemab for Alzheimer DiseaseThe main purpose of this study is to measure the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, watch-and-measure (no experimental treatment required) cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records.
NCT06566170 · Official ClinicalTrials.gov record · Eli Lilly and Company
RecruitingNot a traditional drug phaseIncheon
Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)The purpose of this research is to investigate the long-term effectiveness and safety of new Alzheimer's disease treatments, particularly monoclonal antibody therapies like lecanemab and donanemab, as well as to enhance diagnostic methods for Alzheimer's disease by collecting real-world data from Korean Alzheimer's patients. The goal is to contribute to the precision of Alzheimer's treatment and to measure the impact of these new therapies and diagnostic techniques in clinical practice.
NCT06889818 · Official ClinicalTrials.gov record · Ewha Womans University Mokdong Hospital
RecruitingPhase 2Phoenix, Arizona
Phase 2: testing AADvac1 for Preclinical Alzheimer's DiseaseThe goal of the Alzheimer's Tau Platform (ATP) is to measure the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. This platform trial allows for the simultaneous testing of multiple tau therapies under a shared master protocol.
NCT06957418 · Official ClinicalTrials.gov record · Paul S. Aisen
RecruitingPhase 2 / Phase 3Medellín, Antioquia
Phase 2 / Phase 3: testing Donanemab for Autosomal Dominant Alzheimers DiseaseThe study will be conducted in 2 blinded parts (Part 1 and Part 2). In Part 1, study participants who are mutation carriers will receive active donanemab and non-mutation carriers will receive dummy treatment (placebo)-donanemab for up to 18 months (76 weeks), with a minimum treatment period of 9 months.
NCT06996730 · Official ClinicalTrials.gov record · Banner Health
RecruitingPhase 3Beijing
Phase 3: testing Donanemab for Alzheimer DiseaseThe main purpose of this study is to measure the effects of donanemab (LY3002813) versus dummy treatment (placebo) in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm).
NCT07571161 · Official ClinicalTrials.gov record · Eli Lilly and Company
RecruitingPhase 2Chandler, Arizona
Phase 2: testing Donanemab for Cognitive DysfunctionThe main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.
NCT07589595 · Official ClinicalTrials.gov record · Eli Lilly and Company
RecruitingPhase 3Phoenix, Arizona
Phase 3: testing Donanemab for Alzheimer DiseaseThe main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
NCT07602582 · Official ClinicalTrials.gov record · Eli Lilly and Company